



**9 October 2025**

ASX Announcement

## **Results of Annual General Meeting**

**MELBOURNE Australia, 9 October 2025:** Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) advises that its Annual General Meeting was held today at 11.00 am AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001(Cth), the Company advises that details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

**– Ends –**

**To subscribe to Island's monthly newsletter, [IslandWatch](#), and other forms of email communications, please visit [this page](#) of our website.**

### **Approved for release to the ASX by:**

David Foster (CEO and Managing Director)  
Island Pharmaceuticals Limited  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)

Investors and media, for further information, please contact:

Henry Jordan  
Six Degrees Investor Relations  
+61 (0) 431 271 538  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)

### **About Island Pharmaceuticals**

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more on Island.

# Disclosure of Proxy Votes

## Island Pharmaceuticals Limited

Annual General Meeting

Thursday, 09 October 2025



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	30,886,514	29,413,014 95.23%	71,500 0.23%	1,457,158	1,402,000 4.54%	33,449,564 99.79%	71,500 0.21%	1,457,158	-
2 Election of Jason Carroll as Director	P	38,421,501	37,019,501 96.35%	0 0.00%	31,169,000	1,402,000 3.65%	41,056,051 100.00%	0 0.00%	31,169,000	Carried
3 Approval of increased placement capacity	P	69,586,489	64,538,550 92.75%	3,645,939 5.24%	4,012	1,402,000 2.01%	68,575,100 94.95%	3,645,939 5.05%	4,012	Carried
4 Ratification of issue of First Tranche Shares	P	64,702,677	61,873,677 95.63%	1,427,000 2.21%	1,501,158	1,402,000 2.17%	64,660,227 97.84%	1,427,000 2.16%	1,501,158	Carried
5 Ratification of issue of S3 Consortium Shares	P	64,776,689	61,938,394 95.62%	1,436,295 2.22%	4,813,812	1,402,000 2.16%	65,974,944 97.87%	1,436,295 2.13%	4,813,812	Carried
6 Approval of issue of Shares to Christopher Ntoumenopoulos	P	38,490,501	31,743,373 82.47%	5,345,128 13.89%	31,100,000	1,402,000 3.64%	35,779,923 87.00%	5,345,128 13.00%	31,100,000	Carried
7 Approval of issue of Shares to Phillip Lynch	P	38,490,501	33,759,855 87.71%	3,328,646 8.65%	31,100,000	1,402,000 3.64%	37,796,405 91.91%	3,328,646 8.09%	31,100,000	Carried
8 Approval of issue of Shares to David Foster	P	32,343,672	30,766,172 95.12%	175,500 0.54%	31,100,000	1,402,000 4.33%	34,802,722 99.50%	175,500 0.50%	31,100,000	Carried



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Approval of issue of the Ntoumenopoulos Options to Christopher Ntoumenopoulos	P	38,490,501	31,615,699 82.14%	5,472,802 14.22%	31,100,000	1,402,000 3.64%	35,652,249 86.69%	5,472,802 13.31%	31,100,000	Carried
10 Approval of issue of the Ntoumenopoulos Performance Options to Christopher Ntoumenopoulos	P	32,343,672	25,548,870 78.99%	5,392,802 16.67%	0	1,402,000 4.33%	29,585,420 84.58%	5,392,802 15.42%	0	Carried
11 Approval of issue of the Foster Performance Options to David Foster	P	30,890,526	29,313,026 94.89%	175,500 0.57%	1,453,146	1,402,000 4.54%	33,349,576 99.48%	175,500 0.52%	1,453,146	Carried
12 Approval of issue of Carroll Performance Options to Jason Carroll	P	30,890,526	29,225,352 94.61%	263,174 0.85%	1,453,146	1,402,000 4.54%	33,261,902 99.21%	263,174 0.79%	1,453,146	Carried
13 Approval of issue of Carroll Options to Jason Carroll	P	30,890,526	29,185,352 94.48%	303,174 0.98%	1,453,146	1,402,000 4.54%	33,221,902 99.10%	303,174 0.90%	1,453,146	Carried
14 Approval to issue Advisor Options	P	69,546,501	64,064,355 92.12%	4,080,146 5.87%	44,000	1,402,000 2.02%	68,100,905 94.35%	4,080,146 5.65%	44,000	Carried
15 Approval of issue of Lynch Options to Phillip Lynch	P	38,090,501	19,349,855 50.80%	17,338,646 45.52%	31,500,000	1,402,000 3.68%	22,247,447 54.63%	18,477,604 45.37%	31,500,000	Carried

